TrialThe Lancet. Neurology2019

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.

Diego Cadavid et al.PubMed ↗Publisher ↗

No numbers read from the abstract.